Q1 FY27 earnings call · July 24, 2026

Acutaas Chemicals Ltd Q1 FY27 Earnings Call: Reaffirms 25% Revenue Growth Guidance, Sets Rs. 1,000 Cr CDMO Target

Cofacto ResearchPublished July 24, 20265 min read
Quick summary

Acutaas Chemicals Ltd held its Q1 FY27 earnings call on July 24, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Surges 59% YoY; Margins Expand Sharply

  • Rs.329.7 crore revenue for Q1 FY 2026-2027, up 59.1% YoY, driven predominantly by the Pharma Intermediate segment.
  • Pharma Intermediates revenue of Rs.292.7 crore (+76.5% YoY); Specialty Chemicals fell 10.6% YoY to Rs.37 crore as commodity phase-down offset BFC recovery.
  • Gross profit Rs.190.9 crore, up 73% YoY; gross margin expanded 466 bps to 57.9% on higher pharma mix.
  • EBITDA Rs.113.1 crore (margin 34.3%, +973 bps YoY) aided by gross margin expansion and operational efficiencies; PAT Rs.74.9 crore (margin 22.7%, +151 bps YoY).
  • Net cash and equivalents at Rs.314 crore as of 30 June 2026; working capital days at 99 days (vs. 91 in Q4 FY 2025-2026) on higher inventory.
  • Capacity utilisation: Sachin 83%, Ankleshwar 23%, Jagadia 55% in Q1 FY 2026-2027.
  • Other income fell from Rs.11 crore (Q4 FY26) to Rs.1.8 crore due to a swing in forex — prior quarter included a positive Rs.10 crore forex fluctuation.

25% Revenue Growth Reaffirmed; CDMO Targets & Battery Ramp

  • Management reaffirmed 25% revenue growth guidance for FY 2026-2027 with margins similar to FY 2025-2026 levels.
  • CDMO revenue target of Rs.1,000 crore by FY 2027-2028; four validated products expected to contribute from H2 FY27, each with peak potential of Rs.50-100 crore.
  • Battery chemicals (VC & FEC) plant commissioned with commercial supplies started in Q1; full capacity of 4,000 MT (2,000 MT each) targeted by FY 2028-2029.
  • Electrolyte additive Phase 2 (third product) capex on schedule for completion by end of Q2 FY 2026-2027; contract in place, ramp-up expected from FY 2027-2028.
  • Semiconductor R&D facility commissioned; product development started, with full capacity expected in 3–4 years ("...full capacity expected to be filled in 3–4 years (i.e., by FY2029-2030 to FY2030-2031)").
  • Management developing 30–40 molecules annually for CDMO pipeline; new Sachin pilot plant to support expansion over the next 2–3 years.
  • Commodity chemical rationalization completed for pharma intermediates in FY26; now underway for Specialty Chemicals in FY 2026-2027 to support margin improvement.

Q1 Margin Surge Not Seen as Run-Rate; FY27 Guidance Flat

  • Q1 EBITDA margin of 34.3% is not the FY run-rate — management expects full-year FY 2026-2027 margin to be similar to FY 2025-2026 levels, not at the Q1 peak.
  • Employee cost guided at ~Rs.150 crore for FY 2026-2027, inclusive of increments and one-time bonuses.
  • Segment margins: Pharma Intermediates ~36%, Specialty Chemicals ~24%; battery chemicals are expected to carry lower margins than pharma or CDMO.
  • Indichem business margins will benchmark against existing BFC product margins, not API or pharma intermediates — management called it "very preliminary" to quantify.
  • Product mix shift over the next 3 years (pharma intermediates share from 87% to ~80% by FY 2028-2029) will pressure overall margins as lower-margin battery revenue grows.
  • Other expenses in Q1 in line with prior quarters; savings from solar project and efficiencies expected to keep expenses similar for the rest of FY27.

Rs.56 Crore Spent in Q1; New Land & R&D Center Ahead

  • Q1 FY27 capex of Rs.56 crore (Rs.15 crore at Indichem, Rs.41 crore at ACL site for battery chemicals, pilot plant, maintenance).
  • FY 2026-2027 total capex: ~Rs.50 crore spillover from electrolyte additive and pilot plant plus Rs.40-45 crore maintenance; additional R&D center and land acquisition capex to be announced.
  • New land parcel being acquired for future capacity expansion; Sachin pharma intermediate plant at capacity, Ankleshwar plant expected to fill by FY 2028-2029.
  • Indichem semiconductor plant in Korea ahead of schedule, completion expected by end of Q3 FY 2026-2027; revenue contribution from FY 2027-2028.
  • Electrolyte additive Phase 2 (third product) capex due by end of Q2 FY27; trial runs soon after, with contracted offtake enabling rapid ramp-up.

Focused on Additives; No API Entry; Concentrated CDMO Exposure

  • No plans to enter electrolyte solution or LFP cathode segments — management committed to electrolyte additives only.
  • No API manufacturing — policy of not competing with customers confirmed for FY 2026-2027 and beyond.
  • CDMO revenue concentrated on a few molecules due to rapid growth in one product; management plans to de-risk over coming years through R&D pipeline expansion (no specific timeline).
  • Darolutamide revenue opportunity tied to customer purchase orders — management declined to link to Bayer's improved $5 billion target or doubling of addressable patient pool.
  • Management expects battery business to reach full capacity by FY 2028-2029 driven by robust demand, not supply constraints; a fourth product is in final contract stage.
  • Revenue mix will shift with pharma intermediates declining to ~80% by FY 2028-2029 as battery and semiconductor ramp; overall margin impact is mixed due to lower battery margins.
  • Management declined to provide margin guidance for 5 years citing dependence on future product mix between CDMO and newer businesses.

Pharma Intermediates Dominates; Specialty Chem in Transition

  • Pharma Intermediates: Rs.292.7 crore in Q1 (+76.5% YoY) driven by top products and new molecule traction; segment margin ~36%.
  • Specialty Chemicals: Rs.37 crore (−10.6% YoY) as commodity phase-down partially offset by BFC recovery; full-year FY27 revenue expected to not decline.
  • CDMO within pharma intermediates growing faster than base business; management did not disclose revenue split.
  • Battery chemicals (VC & FEC) capacity of 4,000 MT; commercial supplies started in Q1, ramp-up from Q2 through Q4 FY27.
  • DMA filed for Johnson & Johnson/Caplita molecule; launch awaited (period unspecified).
  • Product with patent expiries in CY 2026/2027 already gaining traction; sufficient capacity exists to meet demand.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.